Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 15;5:14. doi: 10.1038/s41523-019-0110-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Loss of BRCA1 sensitizes cells to ZMC1. a Schematic representation of the mechanisms of ZMC1 reactivating mutant p53^R175H. b The survival of breast cancer cell line SKBR3 (p53^R175H) after knockdown with either control non-target siRNA or BRCA1 siRNA. The cells were treated with 0.01 and 0.005 µM ZMC1. (n = 4) c Western blotting showed the BRCA1 knockdown by control siRNA (ctrl-siRNA) or BRCA1 siRNA (BRCA1-siRNA) in SKBR3 cells. d The survival of MDA-MB-436 and its two BRCA1-reconstituted cell lines (C6 and C15) after ZMC1 treatment. All the three cell lines were transiently transfected with plasmids expressing human mutant p53^R175H (R175H). (n = 4) e The survival of MDA-MB-436 and its BRCA1-reconstituted cell line (C6) after ZMC1 treatment. Both cell lines were transiently transfected with plasmids expressing human wild type p53 (wtp53). (n = 4) f Western blotting showed the proteins expression after 1 μM ZMC1 treatment for 6- and 24-hours in MDA-MB-436 and its BRCA1-reconstituted cell line (C6). Both cell lines were transiently transfected with plasmids expressing human p53^R175H (R175H). g Quantification of ATM and phospho-ATM (p-ATM) in (f). Student t-test; ***p < 0.001. Each survival experiment was repeated 2–3 times (Fig. 1b, d and e)